(Reuters) — Shares in OvaScience (NSDQ:OVAS) were up 8% at 1 point today after the company announced the 1st birth of baby resulting from its experimental Augment fertility treatment.
It took less than 9 months for InPress Technologies to fund and successfully conclude a 1st-in-human trial of its disposable device for treating postpartum hemorrhage, co-founder & CEO Jessie Becker said last week.